Abstracts Archive - Page 1820 of 2425 - ACR Meeting Abstracts

Abstract Number: 1965 • 2015 ACR/ARHP Annual Meeting
T Cell Activation, Proliferation and Differentiation Markers Lack Diagnostic Accuracy for Detecting Active GCA and PMR
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Qi Wang², Mirjam Roffel², Gerda Horst², Abraham Rutgers², Annemieke M.H. Boots² and Elisabeth Brouwer², ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The most important biomarker in GCA and PMR patients is increased erythrocytes sedimentation rate (ESR) and/ or increased serum level of C-reactive protein (CRP).…
Abstract Number: 1966 • 2015 ACR/ARHP Annual Meeting
Active PMR and GCA Is Associated with Changes in Monocyte Subset Composition
Qi Wang¹, Kornelis S.M. van der Geest², Wayel H. Abdulahad¹, Johanna Westra³, Annemieke M.H. Boots¹ and Elisabeth Brouwer¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Hanzeplein 1, Hpc: Aa21, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two closely related syndromes affecting older people. Proinflammatory cytokine IL-6 is found increased in both…
Abstract Number: 1967 • 2015 ACR/ARHP Annual Meeting
Deregulation of Interleukin-22 Pathway in Giant Cell Arteritis
Stefania Croci¹, Alessandro Zerbini¹, Francesco Muratore², Lucia Belloni³, Francesco Ciccia⁴, Luigi Boiardi², Elena Simonazzi³, Alberto Cavazza⁵, Luca Cimino⁶, Antonio Moramarco⁶, Aroldo Rizzo⁷, Maria Parmeggiani⁸ and Carlo Salvarani^9,10, ¹Clinical Immunology, Allergy and Advanced Biotechnologies Unit,, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ²Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ³Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁴Rheumatology Unit, University of Palermo, Palermo, Italy, ⁵Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁷Pathology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy, ⁸. Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁹Rheumatology, Arcispedale S.Maria Nuova, Reggio Emilia, Italy, ¹⁰Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Interleukin-22 (IL-22) is produced by immune cells but acts only on non-hematopoietic cells, particularly at the barrier interface. We thus hypothesized that IL-22 pathway…
Abstract Number: 1968 • 2015 ACR/ARHP Annual Meeting
Distinct Distribution Patterns of Large Vessel Vasculitis Assessed with 18f-FDG PET/CT: Evidence from Principal Component and Cluster Analyses
Alessandra Soriano¹, Giulia Pazzola¹, Pierluigi Boiardi¹, Francesco Muratore¹, Pierluigi Macchioni¹, Raffaella Aldigeri², Massimiliano Casali³, Annibale Versari³ and Carlo Salvarani^1,4, ¹Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy, ³Nuclear Medicine Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ⁴Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, and University of Modena and Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The performance of 18F-FDG PET/CT in the diagnosis and assessment of disease activity of LVV has not been fully established. The interpretation of data…
Abstract Number: 1969 • 2015 ACR/ARHP Annual Meeting
Can We Predict the Relapse of Giant Cell Arteritis?
Alojzija Hocevar, Rok Ješe, Ziga Rotar, Sonja Praprotnik, Matija Tomšič and Saša Čučnik, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Relapses during glucocorticoid (GC) tapering are frequent in giant cell arteritis (GCA). Anemia at the time of GCA diagnosis was a predictor of flare…
Abstract Number: 1970 • 2015 ACR/ARHP Annual Meeting
Incidence and Predictors of Thoracic Aortic Damage in Biopsy-Proven Giant Cell Arteritis: A Single-Institution Cohort Study
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with giant cell arteritis (GCA) are at an increased risk for aortic structural damage; however, the timing and predisposing characteristics for development of…
Abstract Number: 1971 • 2015 ACR/ARHP Annual Meeting
Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis
Matthew J. Koster¹, Sara J. Achenbach², Cynthia S. Crowson², Eric L. Matteson¹, Hilal Maradit Kremers² and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Title: Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in patients aged…
Abstract Number: 1972 • 2015 ACR/ARHP Annual Meeting
Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis
Joanna Robson¹, Amit Kiran², Andrew Hutchings³, Joseph Maskell⁴, Nigel K Arden⁵, Willie Hamilton⁶, Bhaskar Dasgupta^7,8 and Raashid Luqmani⁹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ³Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁴Faculty of Medicine, University of Southampton, Southampton, United Kingdom, ⁵Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Primary Care, University of Exeter, Exeter, United Kingdom, ⁷Southend University Hospital, Southend, United Kingdom, ⁸Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in the UK, with an incidence of 2.2 cases per 10,000 person-years. Cerebrovascular…
Abstract Number: 1973 • 2015 ACR/ARHP Annual Meeting
Giant Cell Arteritis and Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Narat Srivali² and Wonngarm Kittanamongkolchai³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ³Nephrology and hypertension, Mayo Clinic, Rochester, MN
Giant Cell Arteritis and Risk of Cerebrovascular Accident: A Systematic Review and Meta-analysisBackground/Purpose: Several chronic inflammatory disorders, such as systemic lupus erythematosus and psoriatic arthritis,…
Abstract Number: 1974 • 2015 ACR/ARHP Annual Meeting
Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?
Joanna Robson¹, Karolina Lada², Anne Miller³, Wilby Williamson¹, Julia Newton² and Raashid Luqmani⁴, ¹Rheumatology, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Nuffield Orthopaedic Center, Oxford., Oxford, United Kingdom, ⁴Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Physical inactivity is the fourth leading risk factor for global mortality accounting for 6% of deaths. Patients with giant cell arteritis (GCA) are at…
Abstract Number: 1975 • 2015 ACR/ARHP Annual Meeting
Risk of Mortality of Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Catherine Hill¹, Rachel Black², Johannes Nossent³, Carlee Ruediger⁴, Jem Ninan⁵ and Susan Lester⁶, ¹Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ²Medicine, University of Adelaide, Adelaide, Australia, ³Medicine, University of Western Australia, WA, Australia, ⁴Rheumatology, The Queen Elizabeth Hospital, Woodville, Australia, ⁵Rheumatology, Modbury Hospital, Modbury, Australia, ⁶Rheumatology, Basil Hetzel Institute, QEH, Woodville South, Australia
Background/Purpose: Previous studies of mortality associated with GCA have shown conflicting results.We conducted a systematic review and meta-analysis of observational studies to compare the mortality…
Abstract Number: 1976 • 2015 ACR/ARHP Annual Meeting
Corticosteroid Therapy in Giant Cell Arteritis, Predictors for Long-Term Remission
Luigi Boiardi¹, Giovanna Restuccia², Pierluigi Macchioni¹, Francesco Muratore¹, Alberto Cavazza³, Luca Cimino⁴, Raffaella Aldigeri⁵, Mariagazia Catanoso⁶, Nicolò Pipitone⁶ and Carlo Salvarani⁷, ¹Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²Rheumatology Service, Arcispedale S Maria Nuova-IRCCS, 42100, Italy, ³Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁴Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁵Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy, ⁶Rheumatology Service, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁷Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy
Background/Purpose: The aim of our study was to determine the frequency and the predictors of long-lasting remission in a cohort of consecutive patients with biopsy-proven…
Abstract Number: 1977 • 2015 ACR/ARHP Annual Meeting
Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice
Dalifer Freites Núñez¹, Zulema Rosales^1,2, Lucía Arietti¹, Leticia Leon², Inmaculada Morado¹, Benjamín Fernández-Gutiérrez³, Luis Rodriguez-Rodriguez², Juan A Jover¹ and Lydia Abasolo², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: It has is been demonstrated the safety and efficacy of Methotrexate (MTX) in the treatment of Giant Cell Arteritis (GCA) in clinical trials, but…
Abstract Number: 1978 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Large Vessel Vasculitis with Aorta Involvement. Study on 10 Patients Evaluated By Positron Emission Tomoghraphy
Carlotta Nannini¹, Stelvio Sestini², Laura Niccoli³, Emanuele Cassarà⁴, Olga Kaloudi⁵ and Fabrizio Cantini⁶, ¹Rheumatology, Prato Hospital, Prato, Italy, ²Radiology Department, Prato, Italy, ³Prato Hospital, Prato, Italy, ⁴Rheumatology, Hospital of Prato, Prato, Italy, ⁵PRato, Prato Hospital, Prato, Italy, ⁶Prato, Prato, Italy
Background/Purpose: Large vessel vasculitis (LVV) with aorta involvement are often refractory to common immunosuppressive therapy. Due to the pathogenic role of IL-6 in, we prospectively…
Abstract Number: 1979 • 2015 ACR/ARHP Annual Meeting
Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis
Katie Tuckwell¹, Neil Collinson¹, Micki Klearman², Sophie Dimonaco¹, John H. Stone³ and on behalf of the GiACTA Investigators, ¹Roche Products Ltd., Welwyn Garden City, United Kingdom, ²Genentech, South San Francisco, CA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: GiACTA, a randomized, double-blind, placebo-controlled trial of the interleukin-6 receptor alpha inhibitor tocilizumab (TCZ) in patients (pts) with giant cell arteritis (GCA), is the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].